Charles Bankhead is a Staff Writer at MedPage Today. He covers a variety of topics within the themes of medicine and healthcare, including medical specialties, alternative medicine, and diagnostics, while also addressing significant issues such as the FDA, Coronavirus, social issues, crime, and abortion. His work has been featured in Knowledia, MedPage Today, and MDEdge.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Charles Bankhead's focus is primarily on medical research, clinical trials, FDA approvals, and scientific developments in healthcare and pharmaceuticals. His coverage includes citing data from various studies and press releases.
If you are reaching out to Charles, consider providing insights or commentary based on recent medical research findings or clinical trial outcomes. Expert opinions related to FDA approvals, drug therapies, or challenges in specific areas of healthcare could be well-received by him.
Since his geographic focus is not specified but his topics are broad and universal, pitches can come from experts across the globe who have valuable insights into these areas of medical research and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— No invasive cancer increase at 2 years, but editorialists say data don't back active monitoring
By: Charles Bankhead
— Nearly identical 5-year outcomes with no surgery, sentinel lymph node biopsy
By: Charles Bankhead
— News, features, and commentary about cancer-related issues Oral minoxidil promoted hair regrowth with no serious side effects in women
By: Charles Bankhead
— Significant improvement in 5-year distant relapse-free interval with higher risk score
By: Charles Bankhead
— Adding atezolizumab, camrelizumab to chemotherapy improves pCR but not survival endpoints
By: Charles Bankhead
— No improvement in survival or impact on recurrence, but pending studies leave door ajar
By: Charles Bankhead
— Response rate of 70% at day 28 with remestemcel-L Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy
By: Charles Bankhead
— Lack of biomarkers handicaps decision making in era of expanding treatment options
By: Charles
News, features, and commentary about cancer-related issues
By: Charles Bankhead
— Almost half of patients in active surveillance avoided cystectomy during 40 months of follow-up
(833) 317-6278 
